← Back to patent-cliff list
Maxacalcitol
Tier C — Watch / tradeMaxacalcitol
Chugai Pharmaceutical Co., Ltd.
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：VDR
Brand：Oxarol, Prezios
Indications (approved)：Secondary hyperparathyroidism, Hyperparathyroidism
Regional status
US
-
EU
-
China
-
Japan
Approved
2000-07-03
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Maxacalcitol?
Approved indications include: Secondary hyperparathyroidism, Hyperparathyroidism.
When does the Maxacalcitol patent expire?
No public expiry year is available for Maxacalcitol yet; this page updates once verified.
How do I get a quote for Maxacalcitol intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27